RecruitingNCT07131241

PH-DyPred: A Multimodal Dynamic Risk Prediction Study in Pulmonary Hypertension

Research on Dynamic Risk Prediction for Patients With Pulmonary Hypertension Based on Multimodal Data Fusion: A Prospective Observational Study


Sponsor

First Affiliated Hospital of Fujian Medical University

Enrollment

1,000 participants

Start Date

Jun 27, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Pulmonary hypertension (PH) is a progressive cardiopulmonary disease characterized by elevated pulmonary artery pressure and vascular remodeling, which leads to right heart failure and increased mortality. Despite advances in diagnostics, risk stratification remains limited due to the disease's heterogeneity. This study aims to develop and validate a dynamic risk prediction model for PH by integrating multimodal data-including echocardiography, Cardiac MRI, PET-MR, ECG, biomarkers, and clinical features-using advanced machine learning algorithms. The study will establish a prospective cohort of PH patients to explore predictive markers, stratify prognosis, and provide a scientific basis for early warning and individualized management.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Adults aged 18 years or older
  • Pulmonary artery systolic pressure (PASP) ≥35 mmHg as estimated by echocardiography
  • Provided written informed consent

Exclusion Criteria7

  • Severe hepatic or renal insufficiency
  • Malignancy under active treatment
  • Severe infection
  • Active autoimmune disease
  • Major surgery within the past 3 months
  • Pregnant or breastfeeding women
  • Severe psychiatric disorder impairing ability to comply with the study protocol

Locations(1)

The First Affiliated Hospital of Fujian Medical University

Fuzhou, Fujian, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07131241


Related Trials